miR-1258靶向PDL1的频繁甲基化:在多发性骨髓瘤特异性细胞毒性与预后中的意义
miR-1258过表达可抑制增殖、促进凋亡,发挥抑癌作用。
要点
- miR-1258在活动性骨髓瘤中频繁甲基化,MGUS中未见,提示其参与疾病进展。
- miR-1258甲基化沉默导致PDL1过表达,影响骨髓瘤特异性细胞毒性。
核心结论
- miR-1258是一种与宿主基因ZNF385B共同调控的抑癌miRNA,在活动性骨髓瘤而非MGUS中频繁高甲基化,提示其在骨髓瘤进展中获得。
研究设计与样本
- 研究纳入147份样本,包括10份正常血沉棕黄层、8份正常骨髓浆细胞、16种人骨髓瘤细胞系、20份MGUS、63份初诊骨髓瘤和30份复发骨髓瘤样本,采用甲基化特异性PCR检测miR-1258启动子甲基化。
主要发现
- 5-氮杂-2'-脱氧胞苷处理导致启动子去甲基化及ZNF385B/miR-1258重新表达。
- 荧光素酶实验证实PDL1是miR-1258的直接靶标。
- 在完全甲基化的骨髓瘤细胞中过表达miR-1258可减少细胞增殖、增强凋亡,并抑制PDL1,发挥抑癌作用。
临床怎么用
- miR-1258甲基化状态可能作为区分活动性骨髓瘤与MGUS的分子标志,并提示预后。
- miR-1258-PDL1轴为骨髓瘤特异性细胞毒性调节提供潜在靶点。
局限性
- 研究样本量有限,尤其正常对照和MGUS样本较少,需更大规模验证。
- 甲基化与预后关联的机制及临床适用性尚需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
miR-1258 is localised to the first intron of ZNF385B at chromosome 2q31.3. miR-1258 promoter methylation was studied in 147 samples including 10 normal buffy coat, eight normal bone marrow plasma cells, 16 human myeloma cell lines (HMCLs), 20 MGUS, 63 diagnostic myeloma, and 30 relapsed myeloma samples by methylation-specific PCR. In myeloma lines, miR-1258 methylation, verified by pyrosequencing, was detected in 62·5% HMCLs but not normal controls, and expression of miR-1258 correlated with that of ZNF385B. 5-Aza-2'-deoxycytidine resulted in promoter demethylation and ZNF385B/miR-1258 re-expression. Luciferase assay confirmed programmed cell death ligand-1 (PDL1) as a direct target of miR-1258. Over-expression of miR-1258 in completely methylated myeloma cells led to reduced cellular proliferation and enhanced apoptosis, hence a tumour suppressor role, in addition to repression of PDL1. In primary samples, miR-1258 methylation, with lower expression of miR-1258, was detected in 49·2% diagnostic myeloma, imparting an inferior PFS (P = 0·034) in addition to 50·0% relapsed myeloma but not MGUS. Therefore, miR-1258 is a tumour suppressor miRNA co-regulated with its host gene, and frequently hypermethylated in active myeloma instead of MGUS, hence acquired during myeloma progression. Methylation-mediated miR-1258 silencing led to overexpression of PDL1 and inferior PFS, implicating miR-1258 in the modulation of myeloma-specific cytotoxicity.
引用
- Wang LQ, Kumar S, Calin GA, et al. Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. Br J Haematol. 2020. PMID: 32079038. doi:10.1111/bjh.16517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。